Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients.

Development of the secondary to ACEI cough leads to discontinuation of the drugs of this group. Assessing the safety of the ACEIs with further development of customized approaches for their administration is a major scientific and practical problem. The objective of this study was to assess the association of the genetic markers with the development of the adverse drug reaction in the form of secondary to enalapril dry cough in the patients with essential arterial hypertension. Study involved 113 patients with the secondary to enalapril cough and 104 patients without development of the secondary to enalapril adverse drug reaction. The patients carriers of the genotype AA rs2306283 of gene SLCO1B1 had 2-fold higher odds of developing the dry cough than those with the genotypes AG and GG (ОR=2.01, 95%CI=1.10-3.66, р=0.023). Similarly, the patients heterozygous for rs8176746 of gene АВО had 2.3-fold higher odds of developing the ADR in the form of dry cough than the carriers of the genotypes GG and TT (ОR=2.30, 95%CI=1.24-4.29, р=0.008). Statistically significant association between the development of the ADR in the form of secondary to enalapril dry cough and polymorphisms rs2306283 of gene SLCO1B1 and rs8176746 of gene ABO was revealed. © 2023 Walter de Gruyter GmbH, Berlin/Boston.

Citation

Ivan V Sychev, Natalia P Denisenko, Anastasiya A Kachanova, Anna V Lapshtaeva, Ludmila N Goncharova, Karin B Mirzaev, Dmitry A Sychev. Pharmacogenetic predictors of development of secondary to enalapril dry cough in hypertensive patients. Drug metabolism and personalized therapy. 2023 Sep 01;38(3):247-254

Mesh Tags

Substances

PMID: 37201212

search → result